Certara Products - Certara IQ Archives

Video

Modeling Hope: From Patient to Scientist Ellen Swanson on QSP, Breast Cancer, and Hope Through Science

Ellen Swanson, QSP Senior Scientist at Certara, shares her personal journey from breast cancer diagnosis…

CertaraApril 16, 2026

On-Demand Webinar

Portfolio Prioritization for Large and Small Pharma Using Early-Stage Biosimulation

Learn how early-stage biosimulation and mechanistic modeling enable smarter portfolio prioritization before IND-enabling studies. Watch…

CertaraMarch 25, 2026

Video

ADC Development & Differentiation Strategies | Quantitative Systems Pharmacology & MIDD

Learn how model-informed drug development (MIDD) and quantitative systems pharmacology (QSP) support antibody-drug conjugate (ADC)…

CertaraMarch 13, 2026

Conference

Discovery & Development Europe 2026

CertaraMarch 13, 2026

Webinar

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Danielle PillsburyFebruary 23, 2026

Webinar

Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

CertaraFebruary 23, 2026

Webinar

Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs)

CertaraFebruary 23, 2026

On-Demand Webinar

Accelerate Decisions with Certara IQ™: Scalable, AI-Driven QSP for Drug Development

Discover how Certara's AI-powered QSP modeling software, Certara IQ is overcoming challenges in drug development…

CertaraFebruary 17, 2026

Live Events

Certara IQ^™ Global Roadshow

Certara IQ™ is going on the road. From APAC to Europe to North America, our…

CertaraFebruary 12, 2026

Live Events

Certara IQ™ Workshop

CertaraFebruary 11, 2026

Certara Products – Certara IQ

Modeling Hope: From Patient to Scientist Ellen Swanson on QSP, Breast Cancer, and Hope Through Science

Portfolio Prioritization for Large and Small Pharma Using Early-Stage Biosimulation

ADC Development & Differentiation Strategies | Quantitative Systems Pharmacology & MIDD

Discovery & Development Europe 2026

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs)

Accelerate Decisions with Certara IQ™: Scalable, AI-Driven QSP for Drug Development

Certara IQ^™ Global Roadshow

Certara IQ™ Workshop

Newsletter sign up

Quick links

Solutions

Contact